Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience
Patrizia Alvisi,1 Serena Arrigo,2 Salvatore Cucchiara,3 Paolo Lionetti,4 Erasmo Miele,5 Claudio Romano,6 Alberto Ravelli,7 Daniela Knafelz,8 Stefano Martelossi,9 Graziella Guariso,10 Salvatore Accomando,11 Giovanna Zuin,12 Costantino De Giacomo,13 Lucio Balzani,14 Monia Gennari,15 Marina Aloi3 On be...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d27e38911dc24dcfb8c6197a436c88cf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d27e38911dc24dcfb8c6197a436c88cf |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Pediatric Crohn disease Infliximab failure Adalimumab efficacy Adalimumab safety Medicine (General) R5-920 |
| spellingShingle |
Pediatric Crohn disease Infliximab failure Adalimumab efficacy Adalimumab safety Medicine (General) R5-920 Alvisi P Arrigo S Cucchiara S Lionetti P Miele E Romano C Ravelli A Knafelz D Martelossi S Guariso G Accomando S Zuin G De Giacomo C Balzani L Gennari M Aloi M Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience |
| description |
Patrizia Alvisi,1 Serena Arrigo,2 Salvatore Cucchiara,3 Paolo Lionetti,4 Erasmo Miele,5 Claudio Romano,6 Alberto Ravelli,7 Daniela Knafelz,8 Stefano Martelossi,9 Graziella Guariso,10 Salvatore Accomando,11 Giovanna Zuin,12 Costantino De Giacomo,13 Lucio Balzani,14 Monia Gennari,15 Marina Aloi3 On behalf of the SIGENP IBD Working Group 1Pediatric Gastroenterology Unit, Pediatric Department, Maggiore Hospital, Bologna, Italy; 2Pediatric Gastroenterology and Endoscopy Unit, G Gaslini Children’s Hospital, Genoa, Italy; 3Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy; 4Gastroenterology and Nutrition Unit, Meyer Children’s Hospital, Florence, Italy; 5Pediatric Department, Federico II University of Naples, Naples, Italy; 6Pediatric Gastroenterology, University of Messina, Messina, Italy; 7Gastroenterology and GI Endoscopy Unit, University Department of Pediatrics, Children’s Hospital, Brescia, Italy; 8Hepatology and Gastroenterology Unit, Bambino Gesù Hospital, Rome, Italy; 9Department of Pediatrics, Institute of Child Health, IRCSS Burlo Garofolo, Trieste, Italy; 10University of Padua, Padua, Italy; 11Pediatric Department, University of Palermo, G di Cristina Children’s Hospital, Palermo, Italy; 12Pediatric Unit, Buzzi Hospital, Milan, Italy; 13Pediatric Unit, Niguarda Hospital, Milan, Italy; 14Morgagni Hospital, Forlì, Italy; 15Emergency Pediatric Department, S Orsola Hospital, Bologna, Italy Background: Adalimumab (Ada) treatment is an available option for pediatric Crohn’s disease (CD) and the published experience as rescue therapy is limited.Objectives: We investigated Ada efficacy in a retrospective, pediatric CD cohort who had failed previous infliximab treatment, with a minimum follow-up of 6 months.Methods: In this multicenter study, data on demographics, clinical activity, growth, laboratory values (CRP) and adverse events were collected from CD patients during follow-up. Clinical remission (CR) and response were defined with Pediatric CD Activity Index (PCDAI) score ≤10 and a decrease in PCDAI score of ≥12.5 from baseline, respectively.Results: A total of 44 patients were consecutively recruited (mean age 14.8 years): 34 of 44 (77%) had active disease (mean PCDAI score 24.5) at the time of Ada administration, with a mean disease duration of 3.4 (range 0.3–11.2) years. At 6, 12, and 18 months, out of the total of the enrolled population, CR rates were 55%, 78%, and 52%, respectively, with a significant decrease in PCDAI scores (P<0.01) and mean CRP values (mean CRP 5.7 and 2.4 mL/dL, respectively; P<0.01) at the end of follow-up. Steroid-free remission rates, considered as the total number of patients in CR who were not using steroids at the end of this study, were 93%, 95%, and 96% in 44 patients at 6, 12, and 18 months, respectively. No significant differences in growth parameters were detected. In univariate analysis of variables related to Ada efficacy, we found that only a disease duration >2 years was negatively correlated with final PCDAI score (P<0.01). Two serious adverse events were recorded: 1 meningitis and 1 medulloblastoma.Conclusion: Our data confirm Ada efficacy in pediatric patients as second-line biological therapy after infliximab failure. Longer-term prospective data are warranted to define general effectiveness and safety in pediatric CD patients. Keywords: pediatric Crohn’s disease, infliximab failure, adalimumab efficacy, adalimumab safety |
| format |
article |
| author |
Alvisi P Arrigo S Cucchiara S Lionetti P Miele E Romano C Ravelli A Knafelz D Martelossi S Guariso G Accomando S Zuin G De Giacomo C Balzani L Gennari M Aloi M |
| author_facet |
Alvisi P Arrigo S Cucchiara S Lionetti P Miele E Romano C Ravelli A Knafelz D Martelossi S Guariso G Accomando S Zuin G De Giacomo C Balzani L Gennari M Aloi M |
| author_sort |
Alvisi P |
| title |
Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience |
| title_short |
Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience |
| title_full |
Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience |
| title_fullStr |
Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience |
| title_full_unstemmed |
Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience |
| title_sort |
efficacy of adalimumab as second-line therapy in a pediatric cohort of crohn’s disease patients who failed infliximab therapy: the italian society of pediatric gastroenterology, hepatology, and nutrition experience |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/d27e38911dc24dcfb8c6197a436c88cf |
| work_keys_str_mv |
AT alvisip efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT arrigos efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT cucchiaras efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT lionettip efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT mielee efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT romanoc efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT ravellia efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT knafelzd efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT martelossis efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT guarisog efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT accomandos efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT zuing efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT degiacomoc efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT balzanil efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT gennarim efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience AT aloim efficacyofadalimumabassecondlinetherapyinapediatriccohortofcrohnrsquosdiseasepatientswhofailedinfliximabtherapytheitaliansocietyofpediatricgastroenterologyhepatologyandnutritionexperience |
| _version_ |
1718401153413152768 |
| spelling |
oai:doaj.org-article:d27e38911dc24dcfb8c6197a436c88cf2021-12-02T04:37:43ZEfficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience1177-5491https://doaj.org/article/d27e38911dc24dcfb8c6197a436c88cf2019-01-01T00:00:00Zhttps://www.dovepress.com/efficacy-of-adalimumab-as-second-line-therapy-in-a-pediatric-cohort-of-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Patrizia Alvisi,1 Serena Arrigo,2 Salvatore Cucchiara,3 Paolo Lionetti,4 Erasmo Miele,5 Claudio Romano,6 Alberto Ravelli,7 Daniela Knafelz,8 Stefano Martelossi,9 Graziella Guariso,10 Salvatore Accomando,11 Giovanna Zuin,12 Costantino De Giacomo,13 Lucio Balzani,14 Monia Gennari,15 Marina Aloi3 On behalf of the SIGENP IBD Working Group 1Pediatric Gastroenterology Unit, Pediatric Department, Maggiore Hospital, Bologna, Italy; 2Pediatric Gastroenterology and Endoscopy Unit, G Gaslini Children’s Hospital, Genoa, Italy; 3Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy; 4Gastroenterology and Nutrition Unit, Meyer Children’s Hospital, Florence, Italy; 5Pediatric Department, Federico II University of Naples, Naples, Italy; 6Pediatric Gastroenterology, University of Messina, Messina, Italy; 7Gastroenterology and GI Endoscopy Unit, University Department of Pediatrics, Children’s Hospital, Brescia, Italy; 8Hepatology and Gastroenterology Unit, Bambino Gesù Hospital, Rome, Italy; 9Department of Pediatrics, Institute of Child Health, IRCSS Burlo Garofolo, Trieste, Italy; 10University of Padua, Padua, Italy; 11Pediatric Department, University of Palermo, G di Cristina Children’s Hospital, Palermo, Italy; 12Pediatric Unit, Buzzi Hospital, Milan, Italy; 13Pediatric Unit, Niguarda Hospital, Milan, Italy; 14Morgagni Hospital, Forlì, Italy; 15Emergency Pediatric Department, S Orsola Hospital, Bologna, Italy Background: Adalimumab (Ada) treatment is an available option for pediatric Crohn’s disease (CD) and the published experience as rescue therapy is limited.Objectives: We investigated Ada efficacy in a retrospective, pediatric CD cohort who had failed previous infliximab treatment, with a minimum follow-up of 6 months.Methods: In this multicenter study, data on demographics, clinical activity, growth, laboratory values (CRP) and adverse events were collected from CD patients during follow-up. Clinical remission (CR) and response were defined with Pediatric CD Activity Index (PCDAI) score ≤10 and a decrease in PCDAI score of ≥12.5 from baseline, respectively.Results: A total of 44 patients were consecutively recruited (mean age 14.8 years): 34 of 44 (77%) had active disease (mean PCDAI score 24.5) at the time of Ada administration, with a mean disease duration of 3.4 (range 0.3–11.2) years. At 6, 12, and 18 months, out of the total of the enrolled population, CR rates were 55%, 78%, and 52%, respectively, with a significant decrease in PCDAI scores (P<0.01) and mean CRP values (mean CRP 5.7 and 2.4 mL/dL, respectively; P<0.01) at the end of follow-up. Steroid-free remission rates, considered as the total number of patients in CR who were not using steroids at the end of this study, were 93%, 95%, and 96% in 44 patients at 6, 12, and 18 months, respectively. No significant differences in growth parameters were detected. In univariate analysis of variables related to Ada efficacy, we found that only a disease duration >2 years was negatively correlated with final PCDAI score (P<0.01). Two serious adverse events were recorded: 1 meningitis and 1 medulloblastoma.Conclusion: Our data confirm Ada efficacy in pediatric patients as second-line biological therapy after infliximab failure. Longer-term prospective data are warranted to define general effectiveness and safety in pediatric CD patients. Keywords: pediatric Crohn’s disease, infliximab failure, adalimumab efficacy, adalimumab safetyAlvisi PArrigo SCucchiara SLionetti PMiele ERomano CRavelli AKnafelz DMartelossi SGuariso GAccomando SZuin GDe Giacomo CBalzani LGennari MAloi MDove Medical PressarticlePediatric Crohn diseaseInfliximab failureAdalimumab efficacyAdalimumab safetyMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 13, Pp 13-21 (2019) |